BioLargo

PFAS, Battery Tech And Medical Launches Will Shape Markets

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

08 Apr 25

Updated

01 May 25

n/a

AnalystConsensusTarget's Fair Value

n/a

-5.8%

-1.6%

-5.8%

-1.6%

You can edit this narrative until May 12 5:59 AM. Then, changes will post as Updates.

Author's Valuation

US$0.3550.0% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates3

Shared on 01 May 25

Shared on 24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

AnalystConsensusTarget has decreased revenue growth from 10.9% to 8.0%, increased future PE multiple from 71.3x to 82.7x and increased shares outstanding growth rate from 0.0% to 0.0%.

AnalystConsensusTarget Fair Value

US$0.35

50.0% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

-54.85%

Chemicals revenue growth rate

0.61%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.45%

Calculation

US$2.03m

Earnings '28

67.07x

PE Ratio '28

US$135.90m

Market Cap '28

US$135.90m

Market Cap '28

309.60m

No. shares '28

US$0.44

Share Price '28

US$0.44 Share Price '28

Discounted to 2025 @ 7.33% p.a.

US$0.35

Fair Value '25